Report highlights biotech opportunity for metabolic disorders

A new report from industry analyst GlobalData identifies an opportunity for biotech firms to pursue drug candidates targeting metabolic disorders.

The authors note that a large number of gene therapies in development target cardiovascular and metabolic disorders (CVMD), indicating “immense opportunity for biotech companies to pursue drug candidates that target metabolic disorders.”

The report looks at candidates targeting coronary artery disease, critical limb ischemia, diabetic foot ulcers and Pompe disease, in major markets.